We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.80 | 12.60 | 13.00 | 12.80 | 12.60 | 12.60 | 875,875 | 11:13:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -4.69M | -0.0094 | -13.62 | 64M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/11/2023 08:34 | Looking forward to the InvestorMeet presentation today with POLB. Interesting that Cathal will be present as well as David Allmond our new Chief Business Officer. There is no doubt this new team with JS are about to drive commercialisation strategy and growth in 2024. If they follow the Amryt success we are in for multiple returns for those who have the patience to hold for that reward. | adorling | |
09/11/2023 21:16 | discojames, "clearly something very big coming Down the line. Last chance to make some money" Can you please be specific, what's coming down the line and when? I take it you will be loading up at 8p. I'm happy trading. They have zero revenue, yet the mcap is £40m. | sikhthetech | |
09/11/2023 20:56 | disco kid ,Look carefully. The transaction was actually at 13.55. However, I agree that we should be in for a fun day tomorrow. | klosters65 | |
09/11/2023 20:48 | 1.3m buy at 8.5 when buy price was 8.1 at close, huge signal | discojames | |
09/11/2023 19:12 | Nice big buy after hours. I wonder what tomorrow brings ;) | inaminute | |
09/11/2023 16:44 | Doesn't take a genius to see why they are adding this team while on zero revenues - clearly something very big coming Down the line. Last chance to make some money, Sikhthetech. You missed out on 20% already from being a blinkered idiot, while many of us were taking a position you were too bitter to. Need to stop letting your emotions rule over your investment (or lack of) decisions. | discojames | |
09/11/2023 14:46 | Share price was predicted to double soon. But who can you believe. It does seem like news has leaked across the pond? | mam fach | |
09/11/2023 14:34 | Chica, "Well I learned 1 thing this morning our Jeremy is a puppet on a string." As predicted. I suggested last year, CF was still pulling the strings. The company has ZERO revenues and previously they had £1.2m admin costs. Now the costs will increase even further to pay for these new senior recruits. How much will costs rise because of these new senior appointments? sikhthetech - 26 May 2022 - 10:10:21 - 1001 of 2694 Poolbeg Pharma - POLB Re The patents, this is normal business practice in this sector. It's common sense to have patents in place. Re JS. The rampers would say the new person is better than the previous, it's all part of the baseless ramping. JS should have loaded up big time but didn't. That says a lot. Plus CF is still there, so who is pulling the strings??? Whether things are different with JS will only be known once money starts rolling in... As can be seen from the statement which Marvelman posted this won't be known until next year. "with data expected by year end and monetisation to commence thereafter" | sikhthetech | |
09/11/2023 14:21 | ….. some big buy trades going through … um? | adorling | |
09/11/2023 14:12 | Has that feel about it that something big will happen in the next few months…… | adorling | |
09/11/2023 14:09 | Response to RNS bit slow but do the Yanks see the potential? None the less very welcome movement in price. GLA LTH who've held on. | mam fach | |
09/11/2023 13:31 | Excited! #POLB announces former #AmrytPharma execs are joining Poolbeg Pharma leadership! With their proven track record, could repeat building a $billion-dollar biopharma💡 | elrico | |
09/11/2023 12:22 | When Friel was involved in Amryt it was failing! All the original drug candidates failed except Episalvan (Filsuvez) and it was rejected by the FDA and only got thru EMA because it had approval for partial thickness wounds. It was only when he stepped down as a director and let Joe Wiley and Rory Nealon do their work that the Company turned around. That being said very very few original Fastnet Oil and Gas shareholders made money in Amryt as the reverse merger into Aegerion and the Acquisition of Chiasma amounted to well over $1 billion dollars. When I saw the headlines this morning that Amryt management were joining I thought Joe and Rory were coming on board. | chica1 | |
09/11/2023 10:57 | And what a great puppet master. How many shares does he have. POLB is my largest holding and when CF sells the Company, I shall retire. | klosters65 | |
09/11/2023 10:45 | My thoughts exactly. | mam fach | |
09/11/2023 09:41 | Well I learned 1 thing this morning our Jeremy is a puppet on a string. | chica1 | |
09/11/2023 08:54 | Excellent news for #POLB this...A number of key senior members of the former Amryt Pharma plc leadership team are joining Poolbeg Pharma. Cathal Friel of course co-founded Amryt Pharma back in 2015 and floated it on AIM in 2016. Amryt went on to list on Nasdaq and earlier this year, was sold to Chiesi Farmaceutica for $1.48 billion. Cathal's ambition was always to create another billion-dollar biopharmaceutical company. Excellent progress has been made at Poolbeg since IPO and now they plan to follow a similar strategic approach to Amryt which focused upon developing a number of very exciting clinical assets and the acquisition of approved and marketed drugs, which not only generate revenue but also fund the development of a robust pipeline of innovative products. Joining Poolbeg is: David Allmond, former Chief Business Officer at Amryt Pharma who was instrumental in putting in place the global commercial infrastructure in Amryt which supported its revenue growth from c. $1.5bn million when he joined in 2016, to close to US$250 million some six years later. John McEvoy, former Global General Counsel at Amryt, led the acquisition of Aegerion Pharmaceuticals in 2019 and Chiasma Pharmaceuticals in 2021. He also led the company's dual-listing on Nasdaq in 2020 and its subsequent sale to Chiesi in 2023. Laura Maher was Associate Director of Clinical Operations at Amryt where she led the clinical research programmes for multiple products in Amryt's pipeline including Filsuvez®, the world's first approved epidermolysis bullosa treatment. VERY exciting times... https://www.londonst | burtond1 | |
09/11/2023 08:34 | https://x.com/poolbe | inaminute | |
09/11/2023 07:45 | Very interesting RNS. Was little disheartened that share price not moving forward. Confirmation toady that they are strengthening the team with very experienced people.Interesting how the market reacts . GLA | mam fach | |
09/11/2023 07:23 | I think this mornings rns about the former Amryt team coming over is mega ! They would not be joining unless they were sure of the companies potential .. I'm excited again ! GLA | bossyboss | |
08/11/2023 18:18 | A trade of 907,000 shares at 7.2p this morning , then the share price whimpered back to 6.5p bid. | klosters65 | |
08/11/2023 11:55 | We have produced a broad overview for ease of ref for investors of the IMC featuring the exciting #POLB 001 Oncology Programme. | elrico | |
08/11/2023 11:05 | Do I detect, a tremor of stirring in the share price ? | klosters65 | |
07/11/2023 13:49 | Yeah it was too small apparently for Hvivo (think it was Holland) but with the new facilities they could probably take similar testing on board | chica1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions